<DOC>
	<DOCNO>NCT00168818</DOCNO>
	<brief_summary>The objective study determine comparative efficacy safety two oral regimen dabigatran etexilate , compare standard subcutaneous regimen enoxaparin , prevention venous thromboembolism patient primary elective total hip replacement surgery .</brief_summary>
	<brief_title>Dabigatran Etexilate Extended Venous Thromboembolism ( VTE ) Prevention After Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion Inclusion criterion ( select ) : Patients ( 18 year old ) schedule undergo primary , unilateral , elective total hip replacement Written Informed Consent Exclusion criterion Exclusion criterion ( select ) : Patients excessive risk bleeding , example history bleed diathesis major surgery trauma within last 3 month history haemorrhagic stroke follow intracranial pathology : bleeding , neoplasm , AV malformation aneurysm clinically relevant bleed gastric / duodenal ulcer within last 6 month treatment anticoagulant within 7 day prior joint replacement surgery anticipate need study treatment period thrombocytopenia . Active malignant disease current cytostatic treatment Known severe renal insufficiency Liver disease expect potential impact survival , elevate AST ALT &gt; 2x upper limit normal Recent unstable cardiovascular disease history myocardial infarction within last 3 month Premenopausal woman pregnant nursing , childbearing potential practising plan continue practise acceptable method birth control Allergy radio opaque contrast medium iodine , heparin ( incl . heparin induce thrombocytopenia ) dabigatran Contraindications enoxaparin Participation clinical trial last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>